

CASE REPORT

TUBEROUS XANTHOMA :A RARE PRESENTATION OF FAMILIAL HYPERCHOLESTEROLEMIA

¹Workneh Tesfaye, ¹Netsanet Workneh, ²Eshetu Girma

ABSTRACT

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C).FH often leads to accumulation of cholesterol in the skin, where xanthomas can occur. We report a case of FH in an 11 year old female child which is alerted by multiple nodular lesions over the buttock, knee and elbow. Lipid profile showed elevated serum levels of LDL-C in the child and her mother. Biopsy taken from the lesion showed focal aggregates of foamy macrophages with a conclusion of Tuberos Xanthoma.

Key Words: Xanthomas, Familial hypercholesterolemia, LDL-C

INTRODUCTION

There are both ‘heterozygous’ (heFH) and ‘homozygous’ (hoFH) forms of Familial hypercholesterolemia (FH). In the general population, the prevalence of the heFH phenotype has been reported as 1 in 500 and the prevalence of the hoFH form is estimated to be 1 in 1 million.¹The highest prevalence of FH is seen in the Afrikaner population-estimated as 1 in 70 in the heFH form. Xanthomas are well circumscribed lesions in the connective tissue of the skin, tendons or fascia that predominantly consist of foam cells. These specific cells are formed from macrophages as a result of an excessive uptake of LDL particles and their oxidative modification.

Xanthomas particularly affect the tendons: elbows, Achilles tendons, and hands.²There is no single internationally accepted set of criteria for the clinical diagnosis of FH. The most commonly used are the US-MEDPED³, the UK (Simon Broome)⁴ and the Dutch Lipid Clinic⁵ sets of criteria that have been statistically and genetically validated. Genetic testing may give a definitive diagnosis of FH by detection of pathological mutation.⁶

CASE PRESENTATION

An 11 year old female child was presented with a 5 year history of skin lesion. The lesion began from the knee and buttock area

¹Pediatrician, Pediatric endocrinologist, Email: berushaas@yahoo.com

² Pediatric Resident Department of Pediatrics, St. Paul’s Hospital Millennium Medical Collage, Addis Ababa, Ethiopia

and gradually involved her elbow and flexor area of forearm. She was born from a non-consanguineous marriage and her prenatal, natal and postnatal history was uneventful. She had no past history of illness. The parents denied any family history of chronic illness. Her parents were divorced when she was 2 years old and she was raised by her mother. Physical examination revealed normal vital signs and anthropometry. On dermatologic examination there were multiple nodular yellowish colored lesions over the knee (figure 1), buttock (figure 2), forearm (figure 3), and elbow (figure 4), the maximum measuring 4cm by 5cm.

Laboratory examination showed elevated lipid profile with Total Cholesterol of 698 mg/dl, LDL-C of 646.2 mg/dl, HDL-C was

low (27 mg/dl). Triglyceride value was in the normal range. Biopsy taken from the lesion showed focal aggregates of foamy macrophages with a conclusion of Tuberous Xanthoma. The mother's lipid profile was also done and showed elevated LDL-C value with 261.4 mg/dl. Total Cholesterol was also slightly elevated with 322 mg/dl. HDL-C was 43 mg/dl and Triglyceride value was in the normal range.

All investigations for secondary causes of hypercholesterolemia were non-revealing. The patient fulfilled the 'definitive' criteria for FH according to both the UK⁴ and Dutch Lipid Clinic⁵ criteria for clinical diagnosis of FH. The patient was started on low dose of statin and appointed for 6 weeks to follow up clinic.

Figure 1



Figure 2



Figure 3



Figure 4



DISCUSSION

Familial hypercholesterolemia comprises a minimum of three separate genetic conditions due to mutations in the genes for (i) LDLR, (ii) ApoB, and (iii) PCSK9.¹ The consequences of LDLR gene mutations are high total cholesterol and high serum LDL-C.² Plasma levels of key lipoprotein particles, including LDL-C levels, are major determinants of the initiation of changes in vascular endothelial damage, of monocyte differentiation into macrophages and foam cell formation, leading to the development of atherosclerotic lesions⁷ premature coronary artery disease (CAD), peripheral arterial disease⁸ and valvular disease (predominantly aortic stenosis).

Concerning the targets of treatment in FH guidelines from the US NLA and NICE in the UK recommend a reduction in LDL-C

concentration of >50% from levels before treatment in patients with FH^{9,10} First-line treatment for patients with heFH is with statins.^{9,11,12} Ezetimibe, a cholesterol absorption inhibitor, use results in compensatory increase in hepatic LDLRs and an about 20% reduction in LDL-C.¹³ Bile acid sequestrants also have a strong LDL-C lowering effect and are frequently used at high doses in monotherapy when statins alone are not well tolerated or in combination with statins when statins alone are not able to achieve the LDL-C target. Statins may be effective in some hoFH patients.⁹ Ezetimibe combined with a statin resulted in clinically important reductions in LDL-C concentrations in patients with hoFH.¹⁴ The current treatment offered to patients with hoFH is weekly or biweekly apheresis.^{9,11}

Historically, left untreated clinical symptoms of premature cardiovascular disease (CVD) typically manifest in men in their fourth decade and in women in their fifth decade of life in heterozygous FH (heFH). In contrast homozygous FH (hoFH) patients can experience serious cardiovascular events as early as childhood and, on average, in their twenties.^{11,13}

CONCLUSION

Xanthomas are manifestations of an underly-

ing lipid disorder. Therefore patients as well as their family members should be screened for lipid profiles so that appropriate medications can be started earlier to delay the development of premature CGHAD. In our patient, we couldn't trace the father and hence we considered heFH because of epidemiologic reason.¹

Conflict of Interests : None

REFERENCES

1. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia:epidemiology, Neolithic origins and modern geographic distribution. *Crit Rev Clin Lab Sci*2011;48:1–18
2. Nemati MH, Astaneh B. Optimal management of familial hypercholesterolemia:treatment and management strategies. *Vasc Health Risk Manag*2010;6:1079–1088.
3. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol*1993;72:171–176.
4. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ* ;303:893–896.
5. Civeira F. Guidelines for the diagnosis and management of heterozygous familialhypercholesterolemia. *Atherosclerosis* 2004;173:55–68.
6. Nicholls P, Young I, Lytle K, Graham C. Screening for familial hypercholesterolaemia. Early identification and treatment of patients is important. *BMJ* 2001;322:1062
7. Descamps OS, Gilbeau JP, Laysen X, Van LF, Heller FR. Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia. *Eur J Clin Invest* 2001;31:958–965.

8. Kroon AA, Ajubi N, van Asten WN, Stalenhoef AF. The prevalence of peripheral vascular disease in familial hypercholesterolaemia. *J Intern Med* 1995;238: 451–459.
9. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J ClinLipidol*2011;5:133–140.
10. Identification and management of familial hypercholesterolaemia. NICE clinical guideline, CG 71. National Institute for Health and Clinical Excellence website 2008. <http://www.nice.org.uk/cg71> (12 February 2013).
11. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. *BMJ* 2008;337:a1095
12. Aubert I, Emmerich J, Charpak Y, Chanu B, Dachet C, Herlich D, BesseauM,Rouffy J, Jacotot B. Effects of simvastatin on plasma lipids, lipoproteins and apoproteins(A1 and B). 24 cases of major primary hypercholesterolemia. *PresseMed* 1988;17:901–904.
13. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *J Clin Invest* 2003;111:1795–1803.
14. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation* 2002;105:2469–2475.